Evidence map›Paper›PMID 38675226›Full record

ArticlePharmaceutics2024

Performance Characterisation of the Airvo2

Ronan MacLoughlin, Marc Mac Giolla Eain

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06815679 (The Physiological Effects of Nebulized Salbutamol in Patients With Acute Respiratory Failure During HFNC), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06815679 phase2 / phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Physiological Effects of Nebulized Salbutamol in Patients With Acute Respiratory Failure During HFNC

TypeinterventionalSponsorUniversità degli Studi di FerraraRan2025 to 2026Enrolled20ConditionsAcute Respiratory Failure, PneumoniaArmssalbutamol 2.5 mg via vibrating mesh nebulizer (VMN)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ronan MacLoughlinResearch and Development, Science and Emerging Technologies, Aerogen Ltd., Galway Business Park, H91 HE94 Galway, Ireland.ORCID 0000-0002-3164-1607
Marc Mac Giolla EainResearch and Development, Science and Emerging Technologies, Aerogen Ltd., Galway Business Park, H91 HE94 Galway, Ireland.ORCID 0000-0002-0211-2132
Aerogen (Ireland) · IERoyal College of Surgeons in Ireland · IE

Funding

Aerogen (Ireland) N/A
6 · The paper itself

Abstract

High flow oxygen (HFO) therapy is a well-established treatment in respiratory disease. Concurrent aerosol delivery can greatly expediate their recovery. The aim of this work was to complete a comprehensive characterisation of one such HFO therapy system, the Airvo2

Indexed as

adultaerosol drug deliveryaerosol therapyhigh flow oxygen therapyneonatepaediatricvibrating mesh nebuliser

Identifiers

PMID38675226
PMCPMC11053618
OpenAlexW4394999468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.